Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 01/14/2025 at 07:00, 1 year 3 months ago

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101 for viral respiratory infections, sarcopenia, and obesity. The potential partnership aims to develop and commercialize the drug in China's growing pharmaceutical market

Biophytis Exclusive Negotiations Chinese Pharmaceutical Company BIO101 License Viral Respiratory Infections
REGULATED PRESS RELEASE

published on 01/14/2025 at 07:00, 1 year 3 months ago

Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101
Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101. L'objectif est de co-développer et commercialiser le traitement en Chine

Biophytis Négociation Exclusive BIO101 Co-développement Société Pharmaceutique Chinoise
BRIEF

published on 01/08/2025 at 07:05, 1 year 4 months ago

Biophytis obtient des financements pour son programme d'obésité

Investissement Biophytis Refinancement BIO101 Obésité
BRIEF

published on 01/08/2025 at 07:05, 1 year 4 months ago

Biophytis Secures €8.6 Million for Obesity Program

Clinical Development Debt Conversion Obesity Program Biophytis Financing New Investors
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 4 months ago

Biophytis annonce un nouvel apport en cash et une conversion de dettes pouvant atteindre 8,6 M€ pour financer son programme dans l’obésité
Biophytis annonce un nouvel apport en cash de 2,5 M€ et une conversion de dettes jusqu'à 6,1 M€ pour financer son programme dans l'obésité. Opération de refinancement de 8,6 M€ pour consolider sa structure financière et lancer l'étude de phase 2 OBA aux États-Unis

Biophytis Financement Développement Clinique Opération Financière Obésité
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 4 months ago

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program
Biophytis announces new cash contribution and debt conversion totaling €8.6 million to finance obesity program. Strategic financial transaction strengthens company's financial structure for future development

Biophytis Financial Transaction Debt Conversion Obesity Program Cash Contribution
BRIEF

published on 01/06/2025 at 08:35, 1 year 4 months ago

Biophytis Temporarily Suspends Trading of Shares Before Refinancing

Biophytis Biotechnology Refinancing Age-related Diseases Trading Suspension
BRIEF

published on 01/06/2025 at 08:35, 1 year 4 months ago

Biophytis suspend temporairement la cotation de ses actions pour un refinancement

Biophytis Biotechnologie Euronext Growth Refinancement Suspension De Cotation
REGULATED PRESS RELEASE

published on 01/06/2025 at 08:30, 1 year 4 months ago

Biophytis annonce la suspension temporaire de la cotation de ses actions et de ses BSA avant la conclusion d'une opération de refinancement
Biophytis annonce la suspension temporaire de la cotation de ses actions et de ses BSA avant la conclusion d'une opération de refinancement. Pour plus d'informations, visitez www.biophytis.com

Biophytis Biotechnologie Cotation Refinancement Suspension Temporaire
REGULATED PRESS RELEASE

published on 01/06/2025 at 08:30, 1 year 4 months ago

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction
Biophytis temporarily suspends listing of shares and share warrants prior to refinancing transaction. Trading to resume soon

Biophytis Shares Refinancing Listing Suspension

Published on 05/09/2026 at 01:55, 16 hours 21 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 16 hours 36 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 16 hours 46 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 18 hours 16 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 19 hours 15 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/08/2026 at 20:38, 21 hours 38 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 23 hours 3 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 23 hours 14 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 23 hours 47 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 23 hours 47 minutes ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 1 day 23 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 23 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 23 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 23 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 23 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News